Evidence map›Paper›PMID 39440520›Full record

ArticleAnnals of clinical and translational neurology2024

Fulminant leptomeningeal disease diagnosed as comutant H3F3A and FGFR diffuse midline glioma.

Larysa Benistant, Damien Reita, Maleka Schenck, Vincent Castelain, Hélène Cebula, Benoît Lhermitte, Laura Bender

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical and translational neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Larysa BenistantOncology Department, Institut de Cancérologie Strasbourg Europe, 17 Avenue Albert Calmette, Strasbourg, France.
Damien ReitaMolecular Biology Department, University Hospital Strasbourg, 1 Avenue Molière, Strasbourg, France.
Maleka SchenckMedical Reanimation Department, University Hospital Strasbourg, 1 Avenue Molière, Strasbourg, France.
Vincent CastelainMedical Reanimation Department, University Hospital Strasbourg, 1 Avenue Molière, Strasbourg, France.
Hélène CebulaNeurosurgery Department, University Hospital Strasbourg, 1 Avenue Molière, Strasbourg, France.
Benoît LhermittePathology Department, University Hospital Strasbourg, 1 Avenue Molière, Strasbourg, France.
Laura BenderOncology Department, Institut de Cancérologie Strasbourg Europe, 17 Avenue Albert Calmette, Strasbourg, France.ORCID 0000-0003-3486-8505

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diffuse midline gliomas present a particularly intricate and challenging clinical scenario. This rare case involves a patient with comutant H3F3A and FGFR diffuse midline glioma with a clinical presentation of fulminant leptomeningitis. A 22-year-old male presented with fatal and fulminant diffuse leptomeningitis. Next-generation sequencing of plasma and cerebrospinal circulating tumour DNA revealed diffuse midline gliomas with H3F3A and FGFR mutations. Methylome analysis of meningeal tissue collected during autopsy confirmed the diagnosis. Liquid biopsy plays a crucial role in the diagnosis of diffuse midline gliomas, mainly those with exclusively leptomeningeal presentations.

Indexed as

GliomaHistonesMeningeal NeoplasmsBrain NeoplasmsFatal OutcomeHumansMaleMutationReceptors, Fibroblast Growth FactorYoung AdultH3-3A protein, humanHistonesReceptors, Fibroblast Growth Factor

Identifiers

PMID39440520
PMCPMC11572734

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.